Michael Lukason

CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10

Guo-Xiang Ruan, Elizabeth Barry, Dan Yu et al. · Molecular Therapy · 2017 · 266 citations · Full text

Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration

Timothy K. MacLachlan, Michael Lukason, Margaret E. Collins et al. · Molecular Therapy · 2010 · 163 citations · Full text

Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy

Gregory D Hurlbut, Robin J. Ziegler, Jennifer B. Nietupski et al. · Molecular Therapy · 2010 · 134 citations · Full text

Immunology, Pathology, Immunotherapy +16

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization

Peter Pecháň, Hillard Rubin, Michael Lukason et al. · Gene Therapy · 2008 · 106 citations

Ocular Disease, Angiogenesis, Ophthalmology +7

A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung

Simon J. Eastman, Michael Lukason, Jennifer D. Tousignant et al. · Human Gene Therapy · 1997 · 88 citations

New Formulation, Engineering, Molecular Biology +18